Dr. Estape's comments,
The video, and orator is the evidence that which you complain doesn't exist. He's driven the current licensed device +7,000 times, saving and extending patient lives. He's featured in the current Investor Presentation as "The" RAS surgical professional opinion/reference addressing Pre-clinical Validation. From your own purported professional experience, I would think you know what that means. No?
IMO, this video is THE evidence. Its proof of a completely functional, new RAS device design, validated by the expertise and authority of the USPTO. This RAS surgical device has been validated by arguably the pre-eminent Oncological RAS surgeon in the US. Clearly, the video was edited to limit the information that he could have shared regarding ENOS performance. And is intended to be complimentary because the video exists with a purpose. It provides proof of concept, design, performance and successful application in the targeted industry, and market segment.
If the video doesn't contain all of the subject matter, at the level you deem necessary to reach a compliment - please contact TMDI. I'm sure they will edit the video to meet your standards. We won't hold our breath while waiting for those changes. Please feel free to consider this option, as it will likely enhance your position of influence. IMO.
Mark 45 sec. - Professional credentials, experience and specific procedure expertise. +7,000 cases and more as the Assistant Surgeon.
Mark 1:02 - Evaluated +10 different types of surgical instruments
Mark 1:15 - Evaluated camera, visual acuity - as good as he uses today. All of which is a summary, as a complement about the performance of this new device, as it's been awarded by USPTO.
A "successful" procedure requires the entire system to perform exactly as intended. And it did. The camera provides the visual input so the surgeon can manipulate the hand controllers that facilitates the actions required of the instruments to perform each individual step, in sequence, to complete the procedure. THE ENTIRE SYSTEM.
The USPTO has approved the unique characteristics of ENOS nearly 100 times, so far.
ISRG is going to love this new RAS medical device, and all of the defensible IP it brings to the RAS marketplace. If you think MDT is that foolish to let ISRG have a shot at owning it, and the +$20B in future revenue. Should that be the actual outcome, it may not make the Top 5 on the B-School Strategic Blunders List, but it would make the Top 10. Because those schools would be reviewing it over the course of 20-30 years.
Good luck to all. Regards,BK.
